212 related articles for article (PubMed ID: 26277758)
1. Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists.
Wang Y; Yang T; Liu Q; Ma Y; Yang L; Zhou L; Xiang Z; Cheng Z; Lu S; Orband-Miller LA; Zhang W; Wu Q; Zhang K; Li Y; Xiang JN; Elliott JD; Leung S; Ren F; Lin X
Bioorg Med Chem; 2015 Sep; 23(17):5293-302. PubMed ID: 26277758
[TBL] [Abstract][Full Text] [Related]
2. Discovery of carbazole carboxamides as novel RORγt inverse agonists.
Huang Y; Yu M; Sun N; Tang T; Yu F; Song X; Xie Q; Fu W; Shao L; Wang Y
Eur J Med Chem; 2018 Mar; 148():465-476. PubMed ID: 29477887
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.
Wang Y; Cai W; Zhang G; Yang T; Liu Q; Cheng Y; Zhou L; Ma Y; Cheng Z; Lu S; Zhao YG; Zhang W; Xiang Z; Wang S; Yang L; Wu Q; Orband-Miller LA; Xu Y; Zhang J; Gao R; Huxdorf M; Xiang JN; Zhong Z; Elliott JD; Leung S; Lin X
Bioorg Med Chem; 2014 Jan; 22(2):692-702. PubMed ID: 24388993
[TBL] [Abstract][Full Text] [Related]
4. Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.
Gege C; Schlüter T; Hoffmann T
Bioorg Med Chem Lett; 2014 Nov; 24(22):5265-7. PubMed ID: 25305688
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-indanyl benzamides as potent RORγt inverse agonists.
Tian J; Sun N; Yu M; Gu X; Xie Q; Shao L; Liu J; Liu L; Wang Y
Eur J Med Chem; 2019 Apr; 167():37-48. PubMed ID: 30743096
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases.
Sun N; Ma X; Zhou K; Zhu C; Cao Z; Wang Y; Xu J; Fu W
Eur J Med Chem; 2020 Feb; 187():111984. PubMed ID: 31881455
[TBL] [Abstract][Full Text] [Related]
7. Discovery of biaryl carboxylamides as potent RORγ inverse agonists.
Chao J; Enyedy I; Van Vloten K; Marcotte D; Guertin K; Hutchings R; Powell N; Jones H; Bohnert T; Peng CC; Silvian L; Hong VS; Little K; Banerjee D; Peng L; Taveras A; Viney JL; Fontenot J
Bioorg Med Chem Lett; 2015 Aug; 25(15):2991-7. PubMed ID: 26048806
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of new oxadiazole substituted thiazole RORγt inverse agonists through a bioisosteric amide replacement approach.
Steeneck C; Gege C; Kinzel O; Albers M; Kleymann G; Schlüter T; Schulz A; Xue X; Cummings MD; Fourie AM; Leonard KA; Scott B; Edwards JP; Hoffmann T; Goldberg SD
Bioorg Med Chem Lett; 2020 Jun; 30(12):127174. PubMed ID: 32334912
[TBL] [Abstract][Full Text] [Related]
9. Increasing human Th17 differentiation through activation of orphan nuclear receptor retinoid acid-related orphan receptor γ (RORγ) by a class of aryl amide compounds.
Zhang W; Zhang J; Fang L; Zhou L; Wang S; Xiang Z; Li Y; Wisely B; Zhang G; An G; Wang Y; Leung S; Zhong Z
Mol Pharmacol; 2012 Oct; 82(4):583-90. PubMed ID: 22700697
[TBL] [Abstract][Full Text] [Related]
10. Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.
Gege C; Albers M; Kinzel O; Kleymann G; Schlüter T; Steeneck C; Hoffmann T; Xue X; Cummings MD; Spurlino J; Milligan C; Fourie AM; Edwards JP; Leonard K; Coe K; Scott B; Pippel D; Goldberg SD
Bioorg Med Chem Lett; 2020 Jun; 30(12):127205. PubMed ID: 32336498
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel quinazolinedione derivatives as RORγt inverse agonist.
Fukase Y; Sato A; Tomata Y; Ochida A; Kono M; Yonemori K; Koga K; Okui T; Yamasaki M; Fujitani Y; Nakagawa H; Koyama R; Nakayama M; Skene R; Sang BC; Hoffman I; Shirai J; Yamamoto S
Bioorg Med Chem; 2018 Feb; 26(3):721-736. PubMed ID: 29342416
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Biological Evaluation of Retinoic Acid-Related Orphan Receptor γt (RORγt) Agonist Structure-Based Functionality Switching Approach from In House RORγt Inverse Agonist to RORγt Agonist.
Yukawa T; Nara Y; Kono M; Sato A; Oda T; Takagi T; Sato T; Banno Y; Taya N; Imada T; Shiokawa Z; Negoro N; Kawamoto T; Koyama R; Uchiyama N; Skene R; Hoffman I; Chen CH; Sang B; Snell G; Katsuyama R; Yamamoto S; Shirai J
J Med Chem; 2019 Feb; 62(3):1167-1179. PubMed ID: 30652849
[TBL] [Abstract][Full Text] [Related]
13. Structural studies unravel the active conformation of apo RORγt nuclear receptor and a common inverse agonism of two diverse classes of RORγt inhibitors.
Li X; Anderson M; Collin D; Muegge I; Wan J; Brennan D; Kugler S; Terenzio D; Kennedy C; Lin S; Labadia ME; Cook B; Hughes R; Farrow NA
J Biol Chem; 2017 Jul; 292(28):11618-11630. PubMed ID: 28546429
[TBL] [Abstract][Full Text] [Related]
14. Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonists.
Jiang B; Duan JJ; Stachura S; Karmakar A; Hemagiri H; Raut DK; Gupta AK; Weigelt CA; Khan J; Sack JS; Wu DR; Yarde M; Shen DR; Galella MA; Mathur A; Zhao Q; Salter-Cid LM; Carter PH; Dhar TGM
Bioorg Med Chem Lett; 2020 Sep; 30(17):127392. PubMed ID: 32738966
[TBL] [Abstract][Full Text] [Related]
15. Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγt.
Kummer DA; Cummings MD; Abad M; Barbay J; Castro G; Wolin R; Kreutter KD; Maharoof U; Milligan C; Nishimura R; Pierce J; Schalk-Hihi C; Spurlino J; Urbanski M; Venkatesan H; Wang A; Woods C; Xue X; Edwards JP; Fourie AM; Leonard K
Bioorg Med Chem Lett; 2017 May; 27(9):2047-2057. PubMed ID: 28318945
[TBL] [Abstract][Full Text] [Related]
16. Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORγt agonists.
Xia Y; Yu M; Zhao Y; Xia L; Huang Y; Sun N; Song M; Guo H; Zhang Y; Zhu D; Xie Q; Wang Y
Eur J Med Chem; 2021 Feb; 211():113013. PubMed ID: 33272782
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.
Shibata A; Uga K; Sato T; Sagara M; Igaki K; Nakamura Y; Ochida A; Kono M; Shirai J; Yamamoto S; Yamasaki M; Tsuchimori N
Biochem Pharmacol; 2018 Apr; 150():35-45. PubMed ID: 29369782
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Design and Synthesis of Fluorene Derivatives as Novel RORγt Inverse Agonists.
Gabr MT; Abdel-Raziq MS
Chem Biodivers; 2018 Sep; 15(9):e1800244. PubMed ID: 29935095
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanism of Action of RORγt Agonists and Inverse Agonists: Insights from Molecular Dynamics Simulation.
Sun N; Yuan C; Ma X; Wang Y; Gu X; Fu W
Molecules; 2018 Dec; 23(12):. PubMed ID: 30513894
[TBL] [Abstract][Full Text] [Related]
20. Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design.
Narjes F; Xue Y; von Berg S; Malmberg J; Llinas A; Olsson RI; Jirholt J; Grindebacke H; Leffler A; Hossain N; Lepistö M; Thunberg L; Leek H; Aagaard A; McPheat J; Hansson EL; Bäck E; Tångefjord S; Chen R; Xiong Y; Hongbin G; Hansson TG
J Med Chem; 2018 Sep; 61(17):7796-7813. PubMed ID: 30095900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
